AbCellera's Press Kit: Overview, Quotes, Press Mentions, Logos, Photography
AbCellera is a privately held technology company with a drug discovery platform that combines high-throughput microfluidics, big data, machine learning, bioinformatics and genomics to find antibodies that can be used to prevent and treat diseases.
Download Logos & Usage Guidelines
“AbCellera has become a go-to partner for big biopharma antibody discovery efforts.”
Dr. John Hamer, Managing Partner
"Carl and his team have built the kind of company we love to back. They continue to drive internal innovation and attract top quality partners from across the industry. Their disruptive discovery engine has empowered top-tier biotechs, helping them to move their programs more quickly towards the clinic, and has succeeded against some of the most challenging therapeutic targets faced by global pharma. AbCellera’s fresh and cross-disciplinary approach exemplifies the computationally advantaged platforms we seek."
Dr. Christian Itin, Chairman & CEO
"We are delighted to work with AbCellera on the identification of new targeting domains for the development of potential new CAR-T cell therapies."
Alexander Schuth, COO
"We continue to be impressed with the speed of discovery, the quality, and the diversity of the antibodies AbCellera delivers. Through this agreement, we have secured expanded access to an industry-leading technology to accelerate the discovery of antibody-based therapies for patients with neurological diseases."
AbCellera's drug discovery platform searches and analyzes natural immune systems to deliver best-in-class antibody therapies.
No other platform optimizes every single step in the path to discovery.
Explore Our Technology